BetterLife Pharma Inc. (BETRF) Stock

About BetterLife Pharma Inc.

BetterLife Pharma Inc., a biotechnology firm headquartered in Vancouver, Canada, specializes in researching and bringing to market therapeutic compounds designed to address neurological disorders across the globe. The company's core focus involves refining and advancing drug candidates derived from interferon-based technologies, which are intended to leverage the immune system to combat viral infections. Its diverse product pipeline includes BETR-001, targeting conditions such as major depressive disorder, treatment-resistant depression, cluster headaches, and post-traumatic stress disorder. Another candidate, BETR-002, is being developed for benzodiazepine dependency, anxiety, and spasticity. Furthermore, BetterLife Pharma is working on MM-003 for COVID-19 and other respiratory viral infections, MM-001 as a localized intravaginal cream for HPV-induced cervical intraepithelial neoplasia, and AP-002 for cancer treatment. The company also maintains a research collaboration with the University of California San Diego, conducting preclinical behavioral pharmacology studies on TD-0148A, a lysergic acid diethylamide derivative solution. Incorporated in 2002, the company operated as Pivot Pharmaceuticals Inc. before officially changing its name to BetterLife Pharma Inc. in December 2019.

BetterLife Pharma Inc. is headquartered in CA.

BetterLife Pharma Inc. (BETRF) stock trades at $0.15 with a market capitalization of $23.96M. The stock is valued at a price-to-earnings (P/E) ratio of -16.80, price-to-book of -3.33, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.03 and $0.20, and currently trades 25.0% below its 52-week high.

On profitability, BetterLife Pharma Inc. generates a return on equity (ROE) of 19.88%, above the typical market average, return on capital employed of 29.80%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.abetterlifepharma.com